B.J. Monk

525 total citations
57 papers, 367 citations indexed

About

B.J. Monk is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, B.J. Monk has authored 57 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Reproductive Medicine, 23 papers in Obstetrics and Gynecology and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in B.J. Monk's work include Ovarian cancer diagnosis and treatment (31 papers), Endometrial and Cervical Cancer Treatments (23 papers) and Cervical Cancer and HPV Research (9 papers). B.J. Monk is often cited by papers focused on Ovarian cancer diagnosis and treatment (31 papers), Endometrial and Cervical Cancer Treatments (23 papers) and Cervical Cancer and HPV Research (9 papers). B.J. Monk collaborates with scholars based in United States, Spain and Italy. B.J. Monk's co-authors include S. Diane Yamada, Andrés Poveda, Trilok Parekh, Antonio Nieto, Stuart Kaye, Deborah Ricci, P. Santabárbara, Roland E. Knoblauch, Reyna Favis and Lois M. Ramondetta and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

B.J. Monk

54 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B.J. Monk United States	11	191	135	135	104	72	57	367
Maria-Pilar Barretina-Ginesta Spain	10	232 1.2×	243 1.8×	198 1.5×	68 0.7×	65 0.9×	35	511
Giuseppa Maltese Italy	11	215 1.1×	115 0.9×	203 1.5×	84 0.8×	85 1.2×	25	394
Dominique Berton France	11	178 0.9×	365 2.7×	84 0.6×	82 0.8×	74 1.0×	35	481
Lingfang Xia China	15	170 0.9×	172 1.3×	205 1.5×	93 0.9×	56 0.8×	35	485
Lindsey E. Minion United States	8	152 0.8×	170 1.3×	90 0.7×	58 0.6×	50 0.7×	15	438
Lucia Musacchio Italy	15	203 1.1×	283 2.1×	170 1.3×	55 0.5×	53 0.7×	46	551
Gonzalo Giornelli Argentina	5	241 1.3×	110 0.8×	254 1.9×	30 0.3×	36 0.5×	8	421
Shujie Pang China	8	114 0.6×	52 0.4×	64 0.5×	56 0.5×	61 0.8×	22	282
M.Steven Piver United States	12	163 0.9×	64 0.5×	111 0.8×	94 0.9×	51 0.7×	16	299
Toshinori Kawagoe Japan	12	153 0.8×	64 0.5×	221 1.6×	53 0.5×	25 0.3×	35	375

Countries citing papers authored by B.J. Monk

Since Specialization

Citations

This map shows the geographic impact of B.J. Monk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.J. Monk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.J. Monk more than expected).

Fields of papers citing papers by B.J. Monk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.J. Monk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.J. Monk. The network helps show where B.J. Monk may publish in the future.

Co-authorship network of co-authors of B.J. Monk

This figure shows the co-authorship network connecting the top 25 collaborators of B.J. Monk. A scholar is included among the top collaborators of B.J. Monk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B.J. Monk. B.J. Monk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pothuri, Bhavana, Stephanie V. Blank, Tashanna Myers, et al.. (2023). Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO). Gynecologic Oncology. 174. 278–287. 20 indexed citations

Martin, Andrew, Bhavana Pothuri, I. Vergote, et al.. (2022). 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety. Annals of Oncology. 33. S789–S789. 16 indexed citations

O’Malley, David M., et al.. (2022). 19TiP SGNTUC-019 phase II basket study of tucatinib and trastuzumab in solid tumors with human epidermal growth factor receptor 2 alterations: Uterine and cervical cancer cohorts. Annals of Oncology. 33. S389–S390. 1 indexed citations

Vergote, I., E.P. Hamilton, Giorgio Valabrega, et al.. (2022). VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer. Annals of Oncology. 33(4). 448–450. 8 indexed citations

Colombo, Nicoletta, Coraline Dubot, Domenica Lorusso, et al.. (2021). LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study. Annals of Oncology. 32. S1307–S1308. 4 indexed citations

O’Malley, David M., Robert L. Coleman, John L. Hays, et al.. (2021). 818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomized, placebo-controlled phase II trial (RaPiDS/GOG-3028). Annals of Oncology. 32. S769–S770. 1 indexed citations

Colombo, N., Domenica Lorusso, Yong‐Mi Kim, et al.. (2021). 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775). INFM-OAR (INFN Catania). A78.1–A78. 2 indexed citations

Coleman, Robert L., Domenica Lorusso, Christine Gennigens, et al.. (2020). LBA32 Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study. Annals of Oncology. 31. S1162–S1163. 17 indexed citations

Ledermann, Jonathan A., Nicoletta Colombo, Amit M. Oza, et al.. (2020). 1 Avelumab in combination with and/or following chemotherapy vs chemotherapy in treatment-naive patients with ovarian cancer: biomarker analyses from the phase 3 JAVELIN Ovarian 100 trial. A1.1–A1. 5 indexed citations

10.

Slomovitz, Brian M., Allan Covens, Jacobus van der Velden, et al.. (2020). Radiotherapy as an alternative treatment for inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: Results of GROINSS-V II. Gynecologic Oncology. 159. 3–3. 3 indexed citations

11.

Shapira‐Frommer, Ronnie, et al.. (2019). Ofranergene obadenovec (VB-111) an anti-cancer gene therapy induces immunotherapeutic effect in platinum resistant ovarian cancer: Histopathology findings. Gynecologic Oncology. 154. 231–232.

12.

Monk, B.J., Prafull Ghatage, Trilok Parekh, et al.. (2015). Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study. Annals of Oncology. 26(5). 914–920. 53 indexed citations

13.

duPont, Nefertiti C., Mark F. Brady, Robert A. Burger, & B.J. Monk. (2013). Prognostic significance of ethnicity and age in advanced stage ovarian cancer: An analysis of GOG 218. Gynecologic Oncology. 130(1). e21–e22. 5 indexed citations

14.

Monk, B.J., Hsin-Hui Huang, Robert A. Burger, et al.. (2011). Quality of Life Outcomes of a Randomized, Placebo-Controlled Trial of Bevacizumab in the Front-Line Treatment of Ovarian Cancer: a Gynecologic Oncology Group Study. European Journal of Cancer. 47. 12–12. 2 indexed citations

15.

Kaye, Stuart, Nicoletta Colombo, B.J. Monk, et al.. (2010). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Annals of Oncology. 22(1). 49–58. 47 indexed citations

16.

Monk, B.J., Luís Más, J. J. Zarba, et al.. (2009). A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC). Journal of Clinical Oncology. 27(15_suppl). 5520–5520. 11 indexed citations

17.

Vergote, I., Jan B. Vermorken, Éric Pujade-Lauraine, et al.. (2009). 8028 Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older. European Journal of Cancer Supplements. 7(2). 458–458. 7 indexed citations

18.

Schwartz, Peter E., B.J. Monk, Diane Provencher, et al.. (2008). An open-label, single arm, phase II study of IV weekly (days 1 and 8) topotecan in combination with carboplatin (day 1) every 21 days as second-line therapy in subjects with platinum-sensitive relapsed ovarian cancer: First stage results. Journal of Clinical Oncology. 26(15_suppl). 16518–16518. 2 indexed citations

19.

Monk, B.J.. (2007). Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Yearbook of Obstetrics Gynecology and Women s Health. 2007. 386–387. 1 indexed citations

20.

Monk, B.J.. (2006). FDG-PET for Management of Cervical and Ovarian Cancer. Yearbook of Obstetrics Gynecology and Women s Health. 2006. 397–398. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact